Explore

Trendline Trendline
Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways

Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways

Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways
Trendline Trendline
Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies
Trendline Trendline
ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment
Rapid Read Rapid Read
Hemispherian Initiates Clinical Trial for GLIX1 in Glioblastoma Patients

Hemispherian Initiates Clinical Trial for GLIX1 in Glioblastoma Patients

Hemispherian AS, a clinical-stage oncology company, has announced the initiation of a Phase 1/2a clinical trial for its novel small molecule therapeutic, GLIX1, targeting glioblastoma and other high-grade gliomas. The trial, conducted in collaboration with BioLineRx Ltd., aims to evaluate the safety and efficacy of GLIX1, which is designed to activate TET2 and induce tumor-selective DNA damage. The study will be carried out at NYU Langone Health, Northwestern University, and Moffitt Cancer Center, with the first site led by Dr. Alexandra Miller. GLIX1 has shown promising preclinical results, including potent anti-tumor activity and robust blood-brain barrier penetration.
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions
Trendline Trendline
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
Trendline Trendline
ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment
Rapid Read Rapid Read
FDA's 2027 Budget Proposes Permanent Rare Disease Vouchers and Regulatory Reforms

FDA's 2027 Budget Proposes Permanent Rare Disease Vouchers and Regulatory Reforms

The FDA's proposed budget for 2027 includes a $7.23 billion allocation, marking a 3.2% increase from the previous year. This budget aims to transition the FDA from a reactionary to a proactive regulatory system, with reforms such as making the rare pediatric disease priority review voucher program permanent. The budget also proposes a new clinical trial notification pathway to simplify the process for launching Phase 1 trials in the U.S. These initiatives are designed to expedite drug development, enhance national security, and promote transparency, while addressing regulatory burdens that have driven companies to conduct early-stage studies abroad.
Trendline Trendline
Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development